A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2018
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms ZUMA-7
- Sponsors Kite Pharma
- 05 Mar 2018 Status changed from planning to recruiting.
- 04 Nov 2016 New trial record
- 19 Oct 2016 According to a Kite Pharma media release, this trial is expected to enroll first patient in 2017.